Research programme: macrolide anti-inflammatory agents - Isomerase Therapeutics/GlaxoSmithKline
Alternative Names: nPT-eryLatest Information Update: 04 Nov 2017
At a glance
- Originator Biotica Technology
- Developer GSK; Isomerase Therapeutics
- Class Macrolides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Inflammation
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for research development in Inflammation in United Kingdom
- 27 Jan 2011 Candidate optimisation development is ongoing the United Kingdom
- 12 Jan 2009 Early research in Inflammation in United Kingdom (unspecified route)